Comprehensive Analysis for Anti-Cancer Target-Indication Prioritization of Placental Growth Factor Inhibitor (PGF) by Use of Omics and Patient Survival Data

The expression of the placental growth factor (PGF) in cancer cells and tumor microenvironment can contribute to induction angiogenesis, supporting cell metabolism by ensuring an adequate blood supply. Angiogenesis is a key component as it facilitates delivery nutrients oxygen rapidly growing cells. PGF recognized novel target for anti-cancer treatment due its ability overcome resistance existing angiogenesis inhibitors impact on microenvironment. We aimed integrate bioinformatics evidence using various data sources analytic tools target-indication identification prioritize indication across types initial step drug development. analysis included gene function, molecular pathway, protein interaction, mutation type, survival prognosis immune infiltration association with PGF. overall evaluation was conducted given totality evidence, treat where level highly expressed certain type poor well possibly associated level. showed significant several cancers through univariate or multivariate analysis. considered diseases inhibitors, their potential effects PGF, are adrenocortical carcinoma, kidney cancers, liver hepatocellular stomach adenocarcinoma, uveal melanoma.